Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
Charity Divert is working with the Metropolitan Police Service (MPS) to stop reoffending by intervening at the point of detention.
Conservationists are using a technique called ‘tickling’ to round up young field crickets to help establish new populations.
Mark Meechan has raised issues of free speech after being found guilty of a hate crime.